Next Phase Newsletter

A global diagnostics company is looking to form partnerships and make investments in emerging life science companies.  The firm is highly flexible about the structure of its investments, and primarily invests in North America and Europe. The firm looks to act as a long-term, highly activist investor.

The firm primarily invests in the diagnostic imaging sector, including imaging devices and agents, CT and MR technologies, and angiography.  The firm prefers to invest in companies at or near the market approval stage but is open to considering investments in earlier-stage companies.  In addition to imaging technologies, the firm is also interested in cardiology devices, and other interventional devices including delivery devices.

The firm does not provide passive financing; the firm only invests in companies developing products that the firm would eventually market and sell.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Venture Capital firm based in the western United States has raised two funds is looking to make venture-stage minority equity investments. The firm is willing to both lead and co-invest in rounds and considers opportunities around the globe.

The firm is looking to invest in therapeutic development, and is primarily interested in small molecule therapeutics.  The firm may also consider investing in durable medical equipment (including hospital hardware), but in general does not invest in medical devices.  The firm only invests in novel technologies and is not interested in generics or reformulations; the firm is, however, interested in highly complex, targeted drug delivery technologies.  The firm is open to investing in any indication area, and is particularly interested in opportunities in virology and infectious diseases; oncology (particularly immuno-oncology), and cardio/metabolic diseases.  The firm invests in companies at the preclinical or early clinical stages of development.  The firm’s primary criteria is scientific novelty and does not invest in ‘me-too’ or ‘me-better’ opportunities.

The firm is a highly activist investor and prefers to manage the development process after an investment is made.  The firm therefore prefers to partner with virtual biotech companies in order to harness the firm’s relationships with CROs.  The firm prefers to invest in rounds in which a lead investor is already in place.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital division of a global medical device company is looking to make investments into early stage medical devices. The firm’s investments are highly varied in both size and structure; the structure may involve milestone payments, or may be an equity investment.  The firm is looking for companies located globally.

The firm invests in every class of medical devices.  The firm invests strategically in indication areas of interest to its parent company, including cardiovascular devices, diseases of the nervous system, and oncology devices.  The firms current portfolio includes cardiovascular and neurovascular devices, diabetes care, ophthalmic devices, diagnostic devices, surgical devices (including urological devices), aesthetics, and ENT devices.  The firm only invests in devices which have data from animal or human trials that provides evidence that the product will succeed; prototype-stage devices are not of interest.

The firm is looking to invests in medical device companies with competitive, patented technology and which are pursuing solutions to significant unmet medical needs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The Venture investment arm of a health insurance provider is looking to acquire and grow ventures with pre-money valuations from $10M-50M. The firm will consider flexible investment structures on a case-by-case basis and seeks to launch 3-5 new ventures each year. The firm invests worldwide with special interest in geographic areas with a large population of senior citizens. The group seeks technology and services that will be available in the Massachusetts market.

The firm seeks to make strategic acquisitions and investments and is solely motivated by reducing the cost of healthcare through scientific discovery and technology. Primary areas of interest include diagnostics, monitoring, preventative medical technology, automation, hardware, and software. The group will only consider technologies with health related applications.

The firm is especially interested in technologies that will impact the senior or low-income markets, including diabetes prevention and technology that can increase access to seniors. The firm seeks low risk technology; it has not invested in biotech but would consider investments in the space. The firm seeks early stage technology still in development.

The firm seeks companies with a management team experienced in one or more of the following: new ventures, healthcare development, software, mobile technology, healthcare administration, or primary care. The group seeks companies that can benefit from reaching a wide range of users through its parent company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global PE company with dedicated Life Science investment funds is looking to provide seed, venture and growth capital to companies in the life science space.  The firm’s investment size is highly variable depending on the stage and financial needs of each company and the firm has no target number of investments it plans to make over the next 6-9 months. The firm is willing to consider investment located globally.

The firm is focuses on a new investment approach to developing pharmaceutical assets in a capital efficient fashion, to a human proof-of-concept in single asset companies  that are anywhere from 12-18 months to IND to proof of concept (Phase IIa). The fund is currently most interested in small molecule therapeutics or IND-ready biologics for indications of metabolic disease, diseases of the blood, inflammation, and oncology. The firm is also willing to invest in highly differentiated biological compounds if compelling opportunities arise.  The firm is also less inclined to invest into orphan indication.

The firm’s requirements for management teams vary on a case by case basis and the firm is open to discussion in this area.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US-based fund seeks to provide debt financing to companies in the life science and healthcare sectors; financing is offered in the forms of senior secured term loans, cash flow loans, revolving lines of credit, real estate and equipment loans. Loans may vary in size from $500,000 to $50m, with ranges and payment terms varying according to the type of loan provided. The firm typically issues about $400-500m in debt per year. Debt is provided to companies for working capital, growth, expansions, recapitalizations, product licensing or acquisitions, or to purchase equipment or real estate. The firm considers opportunities in the USA, Canada, Europe and Oceania.

In the life science sector, the firm is most interested in companies developing therapeutics and medical devices. The firm considers lending to therapeutic companies with a product in Phase I development or later, or to device companies in clinical development or later.

The firm provides capital to both revenue generating and pre-revenue companies. Typically, capital is deployed to bring a company to the next inflection point (such as break-even or an acquisition). The firm prefers to lend to companies that have already received the backing of a number of institutional investors such as VCs.  The ability of these investors to provide follow-on financing, if necessary, is a key part of the evaluation of an opportunity. When considering management teams, the firm prefers those who have prior industry experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US-based private equity firm founded in 2000 is actively investing from two funds. The firm currently has $150M in AUM. The group typically invests from $8M – 20M over the lifetime of an investment and anticipates investments in 2 – 3 platforms over the next year. Investments in the United States and Canada are of interest.

The firm primarily considers medical devices and diagnostics that overlap with or contribute to the healthcare IT and service landscapes, where they predominantly invest. The firm will consider all classes of medical devices. The group is agnostic in terms of indication.

The firm seeks a board seat and is extremely involved in management of portfolio companies. The group seeks a strong management team that has scaled a company in the past. The group prefers to leads investments but will consider co-investing. Growth-stage companies with products already on the market are the core focus of the firm. Though the firm prefers a positive cash flow, it will consider companies not yet making a profit, if the company has a controlled burn rate. The group will also consider add-on devices not yet on the market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com